Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5. (Q40103248)

17 September 2017

title

Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5. (English)

1 reference

17 September 2017

0 references

0 references

1 reference

Franziska Jönsson

1 reference

17 September 2017

Florian Kreppel

series ordinal

1 reference

17 September 2017

publication date

28 July 2017

1 reference

17 September 2017

1 reference

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Effect of gene therapy on visual function in Leber's congenital amaurosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Safety and efficacy of gene transfer for Leber's congenital amaurosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Impact of natural IgM concentration on gene therapy with adenovirus type 5 vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Blood clearance rates of adenovirus type 5 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Macrophage scavenger receptors and host-derived ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Titer determination of Ad5 in blood: a cautionary note

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Neutralizing antibodies against 33 human adenoviruses in normal children in Rome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Adenovirus serotype 5 hexon mediates liver gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Modifications of Adenovirus Hexon Allow for Either Hepatocyte Detargeting or Targeting With Potential Evasion From Kupffer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Directed evolution generates a novel oncolytic virus for the treatment of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Retargeting FX-binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Engineering targeted viral vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

An Engineered Virus Library as a Resource for the Spectrum-wide Exploration of Virus and Vector Diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-017-1498-Z

Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28755290

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28755290

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28755290

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11262-017-1498-Z

1 reference

Dimensions Publication ID

17 September 2017

1090911295

0 references

1 reference